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Abstract
Background: Brain derived proteins such as 14-3-3, neuron-specific enolase (NSE), S 100b, tau,
phosphorylated tau and Aβ1–42 were found to be altered in the cerebrospinal fluid (CSF) in
Creutzfeldt-Jakob disease (CJD) patients. The pathogenic mechanisms leading to these
abnormalities are not known, but a relation to rapid neuronal damage is assumed. No systematic
analysis on brain-derived proteins in the CSF and neuropathological lesion profiles has been
performed.
Methods: CSF protein levels of brain-derived proteins and the degree of spongiform changes,
neuronal loss and gliosis in various brain areas were analyzed in 57 CJD patients.
Results: We observed three different patterns of CSF alteration associated with the degree of
cortical and subcortical changes. NSE levels increased with lesion severity of subcortical areas. Tau
and 14-3-3 levels increased with minor pathological changes, a negative correlation was observed
with severity of cortical lesions. Levels of the physiological form of the prion protein (PrPc) and
Aβ1–42 levels correlated negatively with cortical pathology, most clearly with temporal and occipital
lesions.
Conclusion: Our results indicate that the alteration of levels of brain-derived proteins in the CSF
does not only reflect the degree of neuronal damage, but it is also modified by the localization on
the brain pathology. Brain specific lesion patterns have to be considered when analyzing CSF
neuronal proteins.
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Background
In recent years, the analysis of the cerebrospinal fluid
(CSF) has become increasingly important to support the
clinical diagnosis in patients with sporadic Creutzfeldt-
Jakob disease (sCJD). Various brain-derived proteins have
been studied in the CSF to date, such as 14-3-3 proteins,
gamma-enolase (neuron-specific enolase, NSE), tau,
phosphorylated tau, S-100b and Aβ1–42  [1-11]. These
studies were mainly focused on diagnostic aspects. Ele-
vated levels of these proteins were used as surrogate
parameters for neuronal damage (14-3-3, tau, gamma-
enolase) or astrocytic gliosis (S-100b), following the idea
that CSF proteins reflect changes in pathological brain
conditions.
Although a lot of information has been gained about
abnormal CSF levels of these proteins, only few publica-
tions report on levels of particular proteins and disease
stage or even brain pathology [12-16]. It was assumed that
those protein levels correlate with neuronal damage or
astrocytic gliosis. However, the question of whether par-
ticular protein level abnormalities reflect changes in cer-
tain brain areas affected has not been addressed so far.
In this study, we have investigated brain-derived proteins
such as the physiological form of the prion protein (PrPC),
14-3-3 proteins, tau, phosphorylated tau, NSE and S-100b
in cerebrospinal fluid (CSF) in patients with sCJD with
respect to the neuropathological lesion profile in these
patients.
Methods
Study design
Patients
The study population comprised 57 sporadic CJD accord-
ing to criteria who were registered at the National Refer-
ence Center for TSE Surveillance in Göttingen from June
1993 to August 2003 with clinical data, CSF samples and
brain lesion profile scoring available (see below) [17-19].
Iatrogenic and familial or genetic cases were excluded.
The study was approved by the Ethic Committee of the
Medical Faculty in Goettingen, Germany, (approvals 11/
11/93 from 18th September 1996, amendments from 11/
11/93 from 12th September 2002 and 30/1/05 from 18th
February 2005). The informed consent of the relatives was
obtained.
Clinical data concerning sex, date of birth/death, age at
disease onset, disease duration, date of lumbar puncture,
were collected from examination protocols and medical
charts.
The analysis of the codon 129 genotype of the prion pro-
tein gene (PRNP) was performed after isolation of
genomic DNA from blood according to standard methods
[20]. None of the cases carried a mutation (n = 55).
Because the primary goal of the study was to analyze the
correlation between brain lesion profiles and CSF markers
and because only of the limited numbers of PrPSc typing,
data were not stratified by different molecular subtypes.
Neuropathology
Nine brain regions were investigated for the degree of
spongiform changes, gliosis and nerve cell loss. They com-
prised five cortical regions (medial frontal gyrus, cingulate
gyrus, inferior temporal gyrus, inferior parietal gyrus and
area striata and parastriata), three subcortical regions
(caudate nucleus, putamen and medio-dorsal thalamus)
and vermis cerebelli. An investigator blinded for clinical
data classified the pathological changes semiquantita-
tively for each section (0–4 points for no change, mild,
moderate, severe or maximal changes) [21,22]. The inten-
sity was estimated for spongiform changes and nerve cell
loss. For gliosis, the quantity of glial proliferation, includ-
ing nuclear pleomorphy and gemistocytic changes of the
cytoplasm, was assessed. A status spongiosus with collaps-
ing tisssue matrix, severe astrocytic gliosis and nearly com-
plete nerve cell loss was considered as the maximal
change. The reliability of the neuropathological scoring
profiles was assessed before and revealed comparable
results between the investigators in former investigations
[22].
Biochemical CSF analysis
The routine investigations of the CSF did not reveal any
abnormalities with respect to cell count and protein pro-
file.
All CSF samples were analyzed with respect to 14-3-3 pro-
teins, neuron specific enolase (NSE), tau, phosphorylated
tau, S-100b, PrPc and Aβ1–42 in the reference laboratory of
the Surveillance Unit in Göttingen according to standards
described previously [2,23-26]
The 14-3-3 capture kit, Repairgenics, Bioproducts (Mainz,
Germany, until July 2003, now Schwerin, Germany), was
used for 14-3-3 detection, LIAISON® NSE for NSE detec-
tion, LIAISON SANGTEC®  100 for S-100b detection,
INNOTEST™ hTauAg by INNOGENETICS for tau detec-
tion, INNOTEST™ Phospho Tau for the detection of the
phosphorylated tau at residue 181, INNOTEST™ β-Amy-
loid (1–42) for Aβ-Amyloid. PrPc (comprising PrPC and
potentially to minor degree PrPSc) concentrations were
determined by using a commercially available ELISA for
detection of the abnormal PrPSc (Platelia BSE detecton kit,
BIO-RAD Laboratories GmbH, Munich, Germany). The
following modifications were made to the test protocol:
the proteinase K digestion step, which is used to degrade
the normal, but not the abnormal form of the prion pro-BMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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tein, was omitted, since we were interested in detecting all
PrPc which was present in the sample. To quantify levels
of PrP, a standard curve using recombinant human prion
protein (Prionics AG, Zurich, Switzerland) was used in
each experiment, according to another PrP-ELISA proto-
col [25,27].
NSE was determined in all 57 patients, tau protein in 56,
phosphorylated tau in 33, S-100b protein in 54, Aβ1–42 in
41, PrPc in 45 and 14-3-3 in 51 cases.
Statistical analysis
A regression analysis with respect to the degree of neu-
ropathological changes in all nine examined brain regions
and the concentrations of the CSF markers was per-
formed.
The statistics software package we used for our calcula-
tions was SigmaStat 3.1 and SigmaPlot 9.0 by Systat Soft-
ware Inc., Point Richmond, USA. A linear regression and
the calculation of the Pearson Product Moment Correla-
tion Coefficient were performed for the analysis of any
trends between neuropathological lesion profiles and
concentrations of CSF markers.
Results
Study population
Clinical data on 57 sCJD cases and the CSF concentration
of tau, phosphorylated tau, 14-3-3, S100b, NSE, PrPc and
Aβ1–42 are given in Tables 1 and 2. Looking at the time of
the lumbar puncture within the whole disease course, 6
patients had their CSF taken in the first third, 12 patients
in the second third and 39 patients during the last third of
the disease course (Table 1). The stratification of the data
by time of lumbar puncture and the exclusion of single
cases with extremely long disease duration or a lumbar
puncture very early at onset did not change the results pre-
sented here (data not shown).
Correlation of neuropathological lesion profiles and 
concentrations of brain-derived proteins in the CSF
The degree of neuropathological changes (spongiform
changes, neuronal loss and gliosis) in nine defined brain
areas was analyzed. The severity of spongiform changes
correlates with neuronal loss and gliosis (data not
shown).
A regression analysis of the neuropathological lesion pro-
files and the concentrations of the CSF markers was car-
ried out. The correlation coefficients were calculated and
significant results (p ≤ 0.05) are indicated (Tables 3, 4, 5).
We analyzed if there is a correlation between the NSE con-
centration in the CSF and neuropathological changes. The
NSE concentrations showed no correlation with the
degree of spongiform change, gliosis and nerve cell loss in
the cortical regions. However, elevated NSE levels corre-
lated significantly with the degree of gliosis in the basal
ganglia and cerebellum and with the degree of spongi-
form changes in the thalamus.
The tau protein levels correlated negatively with the
degree of neuropathological changes in cortical regions. A
positive correlation was also found between the degree of
spongiform changes and gliosis in the cerebellum. The tau
concentrations showed no correlation with the degree of
spongiform changes and neuronal loss in the basal gan-
glia, in contrast to the degree of gliosis in the basal gan-
glia, where a positive correlation was found.
The levels of phosphorylated tau concentrations show
negative correlations with the degree of neuropathologi-
cal changes in cortical regions. A negative correlation was
also found between the degree of neuronal loss and gliosis
in the thalamic region, whereas a positive correlation was
found between spongiform changes and the thalamus.
Spongiform changes in the cerebellum correlated in a pos-
itive way with phosphorylated tau levels. No correlation
was found between the degree of neuropathological
changes and phosphorylated tau levels.
14-3-3 protein levels correlated negatively with the degree
of spongiform changes in the cortical regions and with the
degree of neuronal loss in the thalamus. The 14-3-3 pro-
tein levels showed a slightly positive correlation with the
degree of spongiosis in the thalamus. For other brain
regions, no correlation was observed.
The S 100b concentrations correlated negatively with neu-
ropathological changes cortical regions and with the
degree of gliosis and nerve cell loss in the thalamus. In
contrast to this, a positive correlation was found with the
degree of spongiform change in the thalamus and the
degree of gliosis in the basal ganglia and cerebellum.
PrP concentrations in the CSF were negatively correlated
with the degree of neuropathological changes in most cor-
tical regions. A negative correlation was also found with
the degree of gliosis and neuronal loss in the basal gan-
glia. The PrP levels correlated negatively with the degree of
neuronal loss in the cerebellum and the degree of gliosis
in the thalamus. However, PrPc levels correlated signifi-
cantly in a positive way with the degree of spongiform
changes in the cerebellum.
The Aβ1–42 concentrations were negatively correlated with
the degree of neuropathological changes in all cortical
regions and the basal ganglia. A negative correlation was
also found between the degree of neuronal loss and gliosisBMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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in the thalamus. Aβ1–42 concentrations correlated posi-
tively with spongiform changes in the cerebellum.
A synopsis on correlation of various brain-derived pro-
teins and degree of pathological changes in various corti-
cal and subcortical regions is shown in Table 6. In general,
for cortical lesions, NSE levels do not correlate with sever-
ity of pathological changes (they do not increase further
with lesion severity), whereas all other proteins analyzed
showed a tendency towards lower levels with the increas-
ing severity of pathological changes. This effect was more
pronounced for Aβ1–42 and neuronal loss in temporal
regions, cingulated gyrus and parietal regions. The analy-
sis of the pathological changes in subcortical areas
showed more diverse results. The degree of pathological
changes in the basal ganglia correlated with a tendency of
NSE levels to increase and PrPc  and Aβ1–42  levels to
decrease. The severity of neuronal loss and gliosis in the
thalamus correlated negatively with concentrations of
Aβ1–42, S-100b and phosphorylated tau levels. A positive
correlation was seen for spongiform changes and levels of
14-3-3, NSE, S 100b, and phosphorylated tau.
Figures 1, 2, 3, 4, 5 show the correlation between degree
of neuronal loss in various brain areas and CSF levels of
NSE, tau, 14-3-3, Aβ1–42 and PrPc.
Discussion
In CJD patients, most attention has been concentrated on
investigating the role and the biochemical properties of
the pathological form of the prion protein (PrPSc) in cen-
tral nervous system tissue. Brain derived proteins were
mainly studied with respect to their clinical diagnostic
potential rather than to reflect the severity of brain lesions
in CJD. The mechanisms of elevation of brain-derived
proteins in the CSF in patients with CJD and other acute
neurological diseases are not known in detail and the cur-
rent (yet unproven) hypothesis suggests a leakage into the
CSF following rapid neuronal damage [1,2,28-30].
The earliest markers studied in CJD were NSE and S 100b
proteins, which were shown to be elevated in the CSF dur-
ing the disease progression, but a subsequent study was
done only in one patient with repeated lumbar punctures
[13]. In other neurological diseases, high NSE levels in
CSF and serum were used as a prognostic marker of acute
neuronal damage (e.g. hypoxia or ischemia) and disease
progression [31,32]. In CJD, NSE concentrations
increased to a maximum when the disease activity was
most prominent and returned to normal or mildly ele-
vated levels in the terminal stage [13]. These results imply
that these protein levels can serve as biochemical markers
for the presence of an acute neuronal loss in CJD brain
[13]. In addition, other studies assumed that measure-
ment of the NSE might correlate with the disease progres-
sion and NSE levels decrease with reduced numbers of
remaining neuronal cells [15].
We observed that NSE levels increase with severity of neu-
ronal lesions already when only minor changes take place
and they are clearly correlated to the damage of subcorti-
cal grey matter nuclei, in particular the thalamus, but also
Table 1: Clinical characteristics of the patients included in our study (n = 57)
Sex 27 males, 30 females; male-female ratio 0.9
Age at disease onset (median) 61.5 (23–81)
Codon 129 genotype (n = 55) MM: 39 MV: 3 VV: 13 n.d.: 2
PrPSc type 1: 32
type 2: 9
Duration of disease (months) 4.26 (1.1–34.3)
Onset until lumbar punction (months) 3.02 (0.3–27.8)
Lumbar punction until death (months) 0.94 (0–30.8)
Table 2: Concentrations of the cerebrospinal fluid (CSF) markers in CJD
CSF marker median (range) reference cut-off*
NSE (n = 57) 70 (9–200) ng/ml 12.5 ng/ml
tau (n = 56) 6764 (3772–27770) pg/ml 195 pg/ml
phosphorylated tau (n = 33) 55 (18.4–138) pg/ml 61 pg/ml
14-3-3 (n = 51) 984 (410–5387) ng/ml 200 ng/ml
S 100b (n = 54) 8 (1.4–39.2) ng/ml 2 ng/ml
PrP (n = 45) 15.7 (1–40.9) ng/100ml 22 ng/100ml
Aβ1–42 467 (143–959) pg/ml 849 pg/ml
*: data were taken according to the manufacturers instruction in cases where commercially developed kits are available, otherwise calculated based 
on results from non-neurological controls from our study (14-3-3 and PrP)BMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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Table 4: Severity of lesion and concentrations of CSF markers (correlation coefficient): Neuronal loss
Cortical regions Subcortical regions Cerebellum
CG° MFG° ITG° IPG° AS° Putamen Caudate ncl. MDT°
NSE 0.0183 -0.0846 0.0428 -0.0769 -0.0586 0.216 0.216 -0.114 0.202
Tau -0.233 -0.229 -0.159 -0.276 -0.158 0.121 0.0516 -0.257 -0.140
Tau phosphorylated -0.216 -0.236 -0.337 -0.454* -0.505* -0.128 -0.130 -0.235 -0.058
14-3-3 -0.146 -0.170 -0.103 -0.154 -0.118 0.0184 0.0698 -0.266 -0.127
S 100b -0.169 -0.203 -0.192 -0.344* -0.282* 0.195 0.199 -0.254 -0.0115
PrP -0.240 -0.219 -0.457* -0.318 -0.511* -0.260 -0.144 -0.159 -0.279
Aβ1–42 -0.386 -0.295 -0.661* -0.315 -0.488* -0.387 -0.302 -0.321 -0.0136
° MDT: medio-dorsal thalamus
CG: cingulate gyrus
MFG: medial frontal gyrus
ITG: inferior temporal gyrus
IPG: inferior parietal gyrus
AS: area striata
* significant, p ≤ 0.05
Table 3: Severity of lesion and concentrations of CSF markers (correlation coefficient): Spongiform changes
Cortical regions Subcortical regions Cerebellum
CG° MFG° ITG° IPG° AS° Putamen Caudate ncl. MDT°
NSE 0.0709 0.0731 -0.0351 -0.0485 -0.0267 0.164 0.14 0.305* 0.034
Tau -0.173 -0.313* -0.219 -0.309* -0.217 -0.0158 -0.0963 0.024 0.239
Tau phosphorylated -0.302 -0.0729 -0.227 -0.440* -0.195 -0.0431 0.0466 0.282 0.375
14-3-3 -0.142 -0.0968 -0.275 -0.317 -0.198 0.0631 0.190 0.246 0.179
S 100b -0.0686 -0.0459 -0.303* -0.282 -0.359* 0.0893 0.0864 0.242 -0.005
PrP -0.276 -0.0955 -0.307 -0.364* -0.335* 0.0109 -0.0289 0.00314 0.451*
Aβ1–42 -0.453* -0.233 -0.560* -0.356* -0.426* -0.159 -0.248 0.0489 0.465*
° MDT: medio-dorsal thalamus
CG: cingulate gyrus
MFG: medial frontal gyrus
ITG: inferior temporal gyrus
IPG: inferior parietal gyrus
AS: area striata
* significant, p ≤ 0.05
Table 5: Severity of lesion and concentrations of CSF markers (correlation coefficient): Gliosis
Cortical regions Subcortical regions Cerebellum
CG° MFG° ITG° IPG° AS° Putamen Caudate ncl. MDT°
NSE -0.0553 -0.0280 0.0104 -0.0345 -0.0445 0.298* 0.265* 0.0413 0.386*
Tau -0.242 -0.174 -0.178 -0.160 -0.207 0.141 0.254 -0.0726 0.236
Tau phosphorylated -0.423* -0.175 -0.496* -0.479* -0.536* -0.131 -0.111 -0.260 -0.090
14-3-3 -0.189 -0.155 -0.185 -0.0348 -0.114 0.0775 0.198 -0.132 -0.110
S 100b -0.261 -0.188 -0.195 -0.271 -0.245 0.262 0.323* -0.236 0.321
PrP -0.344* -0.260 -0.426* -0.383* -0.511* -0.250 -0.168 -0.409* -0.026
Aβ1–42 -0.517* -0.387* -0.495* -0.396* -0.462* -0.306 -0.357* -0.387* 0.038
° MDT: medio-dorsal thalamus
CG: cingulate gyrus
MFG: medial frontal gyrus
ITG: inferior temporal gyrus
IPG: inferior parietal gyrus
AS: area striata
* significant, p ≤ 0.05.BMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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the basal ganglia. Of interest, NSE levels increase when the
degree of cortical and subcortical changes is small and do
not increase further with more pronounced neuronal
damage or gliosis of cortical structures. NSE was the only
marker for which we observed such a correlation.
Elevated levels of protein 14-3-3 were reported in 80–95%
of patients with sCJD [1,2,18]. The amount of 14-3-3 in
the CSF is thought to be linked to the degree of neuronal
destruction and to the disease stage. In our study, 14-3-3
levels correlated negatively with the degree of spongiform
changes in cortical areas and with the degree of neuronal
loss in the thalamus.
In our study, the highest correlation coefficients were
obtained for Aβ1–42  concentrations and the degree of
spongiform change, gliosis and nerve cell loss in the infe-
rior temporal gyrus, the area striata and cingulate gyrus.
Significant correlation was found for the degree of spong-
iform changes in the cerebellum and Aβ1–42. There were
also high correlations between phosphorylated tau con-
centrations and the degree of gliosis in most cortical
regions, the degree of nerve cell loss in the area striata and
the degree of spongiform change and nerve cell loss in the
inferior parietal gyrus.
Tau and Aβ1–42 levels were initially studied in patients
with Alzheimer's disease and only later were shown to fol-
low a similar pattern in CJD (elevated tau and decreased
Aβ1–42 levels). The pathogenesis of tau-elevation in the
CSF in various forms of dementia is thought to be attrib-
utable to the degree of neuronal cell death [33], but an
early increase of CSF tau in AD is not explained by this
hypothesis [34]. A recent study demonstrated that the CSF
tau level correlates significantly with right frontal and left
temporal cortical atrophy in Alzheimer's disease [35].
These results are partly in line with our observations in
CJD on a significant correlation between tau levels and
the degree of spongiform changes in the frontal cortex.
Tau protein levels in the CSF have been studied with
respect to disease duration and disease stage in CJD
[12,36]. Tau concentrations were lower in CJD patients
with a long duration of disease and were lowest at the
onset or at the end stage of the disease [12]. Our data
explain and extend this observation. After an increase with
minor lesion severity, tau protein levels decrease, but stay
abnormal in the CSF with more severe cortical lesions in
CJD.
The PrPc concentrations showed a high correlation with
the degree of gliosis and nerve cell loss in the area striata
and the inferior temporal gyrus and with spongiform
changes in the cerebellum. Levels of PrPc  and Aβ1–42
clearly correlated with the degree of pathology in cortical
structures, but not with basal ganglia and thalamic
pathology in CJD. This pattern was consistent in the anal-
ysis of various cortical regions and the most striking effect
was seen for Aβ1–42 when compared to the degree of lesion
severity in the temporal lobe and cingulate gyrus.
Conclusion
Taken together, we observed three different patterns of
CSF protein levels associated with the degree of cortical
and subcortical changes. The first one was seen for NSE.
Levels increased with only mild cortical and subcortical
changes and increased further with the degree of subcorti-
cal changes.
Table 6: Synopsis of the degree of pathological changes and levels of various brain-derived proteins in the CSF
Spongiform change/neuronal loss/gliosis *
Cortical Regions Subcortical Regions Cerebellum
basal ganglia thalamus
NSE ↔/↔/↔↔ /↑/↑↑ /↔/↔↔ /↑/↑
tau ↓/↓/↔↔ /↔/↑↔ /↓/↔↑ /↔/↑
phosphorylated tau ↓/↓/↓↔ /↔/↔↑ /↓/↓↑ /↔/↔
14-3-3 ↓/↔/↔↔ /↔/↔↑ /↓/↔↔ /↔/↔
S 100b ↓/↓/↓↔ /↔/↑↑ /↓/↓↔ /↔/↑
PrP ↓/↓/↓↔ /↓/↓↔ /↔/↓↑ /↓/↔
Aβ1–42 ↓/↓**/↓↓ /↓/↓↔ /↓/↓↑ /↔/↔
*: within the cells in the table the first arrow shows spongiform change, the second shows nerve cell loss and the third gliosis; only the strongest 
neuropathological changes among the different regions are shown in the table
**: strong correlation
↔ correlation coefficient from -0.2 to +0.2: no correlation
↑ correlation coefficient from +0.2 to +0.6: weak correlation
↓ correlation coefficient from -0.2 to -0.6: weak correlation.BMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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Correlation between CSF levels of neuron-specific enolase and degree of neuronal loss in various brain areas Figure 1
Correlation between CSF levels of neuron-specific enolase and degree of neuronal loss in various brain areas. (- - - - - - cut-off 
12.5 ng/ml).BMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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Correlation between tau CSF levels and degree of neuronal loss in various brain areas Figure 2
Correlation between tau CSF levels and degree of neuronal loss in various brain areas. (- - - - - - cut-off 195 pg/ml).BMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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Correlation between 14-3-3 CSF levels and degree of neuronal loss in various brain areas Figure 3
Correlation between 14-3-3 CSF levels and degree of neuronal loss in various brain areas. (- - - - - - cut-off 200 ng/ml).BMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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Correlation between PrP CSF levels and degree of neuronal loss in various brain areas Figure 4
Correlation between PrP CSF levels and degree of neuronal loss in various brain areas. (- - - - - - cut-off 22 ng/100 ml).BMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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Correlation between Aβ1–42 CSF levels and degree of neuronal loss in various brain areas Figure 5
Correlation between Aβ1–42 CSF levels and degree of neuronal loss in various brain areas. (- - - - - - cut-off 849 pg/ml).BMC Neurology 2006, 6:35 http://www.biomedcentral.com/1471-2377/6/35
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The second pattern was seen for tau and 14-3-3. There is a
clear elevation of the levels of these proteins in the CSF in
disease stages when the degree of spongiform changes,
neuronal loss and gliosis in cortical areas are relatively
small. In later stages, the levels correlate with the degree of
neuronal damage in cortical structures and decline. One
can only speculate on the mechanisms for this finding; a
potential for increased synthesis or upregulation at early
stages when the brain damage is relatively small cannot
completely be excluded [37,38].
A completely different mechanism must be discussed for
PrPc and Aβ1–42. Normal levels are measured in the CSF
for those proteins at initial stages. With increasing severity
of cortical lesions they decrease. Levels of PrPc and Aβ1–42
levels are independent of the degree of the brain damage
in subcortical areas. Since PrPc is mainly synthesized in
neurons, one can assume that PrPc CSF levels are deter-
mined by the degree of neuronal loss, mainly in cortical
areas [39]. Among the latter, pathological changes in the
inferior temporal lobe seem to have the most effect on
PrPc and Aβ1–42 levels in the CSF.
To conclude, brain specific lesion patterns have to be con-
sidered when analyzing CSF neuronal proteins.
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